Monopar Therapeutics (MNPR) Q2 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on ALXN1840 for Wilson disease and MNPR-101 radiopharmaceuticals for oncology, with multiple programs in late preclinical and clinical stages.

• Assumed full responsibility for ALXN1840 after IND transfer from Alexion, with NDA submission planned for early 2026.

• Two active clinical trials for MNPR-101 radiopharmaceuticals, with expanded access program authorized in the U.S.

• Preclinical work continues on MNPR-101-Ac, with plans to enter clinical trials in the future.

• Management estimates current cash sufficient to fund operations through at least December 31, 2026.

Financial highlights

• Cash, cash equivalents, and investments totaled $53.3 million as of June 30, 2025.

• Net loss was $2.45 million for Q2 2025, compared to $1.72 million in Q2 2024; net loss for the six months ended June 30, 2025, was $5.08 million, up from $3.36 million year-over-year.

• Operating expenses increased to $3.23 million in Q2 2025 from $1.79 million in Q2 2024, driven by higher R&D and G&A costs, including stock-based compensation.

• Interest income rose significantly due to higher cash balances from late 2024 financings, increasing by $707,294 year-over-year.

• No revenue generated to date; accumulated deficit reached $80.9 million as of June 30, 2025.

Outlook and guidance

• Current funds expected to support operations, NDA filing for ALXN1840, and advancement of radiopharmaceutical pipeline through at least end of 2026.

• Anticipates continued increases in R&D and G&A expenses as clinical and preclinical programs progress.

• Future capital needs will depend on clinical progress, regulatory outcomes, and potential business development activities.